Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZW251 |
| Synonyms | |
| Therapy Description |
ZW251 is an antibody-drug conjugate (ADC) comprising an antibody targeting GPC3 linked to the camptothecin-derived topoisomerase I inhibitor ZD06519, which potentially induces cytotoxicity in tumor cells expressing GPC3 and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2658). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZW251 | ZW-251|ZW 251 | GPC3 Antibody 7 | ZW251 is an antibody-drug conjugate (ADC) comprising an antibody targeting GPC3 linked to the camptothecin-derived topoisomerase I inhibitor ZD06519, which potentially induces cytotoxicity in tumor cells expressing GPC3 and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2658). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07164313 | Phase I | ZW251 | A Study of ZW251 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |